Stockscreener 앱 받기
104.51
2.25%
2.391
Nuvalent Inc 주식(NUVL)의 최신 뉴스
The Technical Signals Behind (NUVL) That Institutions Follow - Stock Traders Daily
Nuvalent, Inc. (NUVL) Stock Analysis: Evaluating a Potential 41.52% Upside in Biotech Innovation - DirectorsTalk Interviews
How Investors May Respond To Nuvalent (NUVL) NDA Filing And Early Zidesamtinib Response Data - Yahoo Finance
Bernstein initiates coverage of Nuvalent (NUVL) with outperform recommendation - MSN
Nuvalent’s SWOT analysis: biotech stock gains momentum on clinical data By Investing.com - Investing.com South Africa
Nuvalent’s SWOT analysis: biotech stock gains momentum on clinical data - Investing.com
NUVL Initiated Coverage by Bernstein -- Rating Set to Outperform - GuruFocus
Bernstein Initiates Nuvalent at Outperform - Moomoo
Nuvalent (NUVL) Receives Outperform Rating with $189 Target from Bernstein - GuruFocus
Bernstein initiates Nuvalent stock coverage with outperform rating By Investing.com - Investing.com Nigeria
Bernstein initiates Nuvalent stock coverage with outperform rating - Investing.com
Nuvalent Highlights Upcoming Data Presentations for Neladalkib and Zidesamtinib at the 2026 American Society of Clinical Oncology Annual Meeting - PR Newswire
Nuvalent ASCO 2026 Data Puts Neladalkib And Zidesamtinib In Focus - Sahm
Nuvalent Highlights Corporate and Pipeline Achievements and Repo - GuruFocus
CCORF Maintains Nuvalent(NUVL.US) With Buy Rating, Maintains Target Price $126 - Moomoo
Assessing Nuvalent (NUVL) Valuation After Recent Share Price Volatility And DCF Upside Signals - simplywall.st
Stifel Maintains Nuvalent (NUVL) Buy Recommendation - MSN
Precision Trading with Nuvalent Inc. (NUVL) Risk Zones - Stock Traders Daily
J.P. Morgan Maintains Nuvalent(NUVL.US) With Buy Rating, Cuts Target Price to $147 - Moomoo
TradingKey - TradingKey
H.C. Wainwright Maintains Nuvalent(NUVL.US) With Buy Rating, Maintains Target Price $155 - Moomoo
Nuvalent, Inc. (NUVL) Stock Analysis: 35% Potential Upside Amid Strong Buy Ratings - DirectorsTalk Interviews
LifeSci Capital Maintains Nuvalent(NUVL.US) With Buy Rating, Maintains Target Price $142 - Moomoo
Truist Financial Maintains Nuvalent(NUVL.US) With Buy Rating, Maintains Target Price $140 - Moomoo
Guggenheim Maintains Nuvalent(NUVL.US) With Buy Rating, Cuts Target Price to $151 - Moomoo
A Quick Look at Today's Ratings for Nuvalent(NUVL.US), With a Forecast Between $140 to $152 - Moomoo
Nuvalent: Buy Rating Reiterated on Strong Oncology Pipeline, Commercial Readiness, and Unchanged $142 Price Target - TipRanks
Nuvalent, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Nuvalent Inc-A (NASDAQ:NUVL) Stock Edges Higher After Q1 2026 Earnings Miss as Investors Focus on Pipeline Milestones - ChartMill
Nuvalent (NUVL) widens Q1 loss as R&D spend rises and cash tops $1.3B - Stock Titan
Nuvalent (Nasdaq: NUVL) posts Q1 loss, advances dual lung cancer NDAs - Stock Titan
Nuvalent Highlights Recent Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2026 Financial Results – Company AnnouncementFT.com - Financial Times
Nuvalent CEO James Porter sells $3.05m in NUVL shares, exercises options - Investing.com Canada
Nuvalent(NUVL.US) Officer Sells US$3.05 Million in Common Stock - Moomoo
Nuvalent (NUVL) CEO exercises options and sells 30,000 common shares - Stock Titan
Nuvalent earnings in focus as drug launch looms By Investing.com - Investing.com South Africa
Nuvalent earnings in focus as drug launch looms - Investing.com UK
FMR LLC reports 9.25M Nuvalent shares (12.6%) (NASDAQ: NUVL) - Stock Titan
Nuvalent CFO Balcom sells $1.13m in company stock By Investing.com - Investing.com South Africa
Nuvalent CFO Balcom sells $1.13m in company stock - Investing.com
Nuvalent (NUVL) CFO sells 11,430 shares, exercises options under plan - Stock Titan
Nuvalent to Present Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC at WCLC 2025 Presidential Symposium - Quantisnow
Nuvalent, Inc. (NUVL) Stock Analysis: Exploring a 43.75% Potential Upside with Promising Oncology Innovations - DirectorsTalk Interviews
Insider Selling: Nuvalent (NASDAQ:NUVL) Insider Sells 5,500 Shares of Stock - MarketBeat
Nuvalent Insider Sold Shares Worth $547,524, According to a Recent SEC Filing - marketscreener.com
Nuvalent Insider Sold Shares Worth $545,691, According to a Recent SEC Filing - marketscreener.com
Nuvalent (NUVL) CLO sells shares, exercises options in 10b5-1 plan - Stock Titan
Nuvalent (NUVL) CDO nets 5,500-share sale after option exercise - Stock Titan
Canaccord Genuity Sticks to Their Buy Rating for Nuvalent (NUVL) - The Globe and Mail
2.25%
0.46%
자본화:
|
볼륨(24시간):